Immedica speaker at the Nordic American Life Science Conference 2019 in New York City

news

Commercialization of niche specialty care pharmaceutical products in Europe is a truly complex and multifaceted process. As a demonstration of its expertise in this area, Immedica was in December invited to present at the 2019 Nordic American Life Science Conference in New York City gathering more than 200 participants representing mainly US investors as well as American and Nordic life science companies.

In New York, Immedica was represented by its head of business development, Håkan Garpenstrand, who in an expert panel session discussed regional deal making between North America and Europe, cross company alliance management, and innovation in the Nordic life science environment.

At the conference it was recognized that Immedica in short time has conducted several transactions where European rights has been in focus, and that these transactions have been conducted creating value for both parties, not least through mutually fruitful alliance management.

The two-day conference was hosted by DNB, Business Sweden, and Nasdaq, and featured company presentations from some of the leading healthcare companies in the Nordics, expert panel discussions, and inspiring key note speakers.

Immedica thanks the hosts. We are delighted to have been able to share insights frNordic American Life Scienceom its considerable experience from regional European business development.

 

About Immedica Pharma

Immedica is a fast-growing private niche pharma group. Its headquarter is based in Stockholm, Sweden, and it has commercial coverage across Europe and the Middle East.

Immedica provides significant know-how and experience from commercialization of niche/specialty care products across Europe and the Middle East, and the company’s management team has an outstanding track record of operating niche pharma products internationally. Immedica has capabilities to provide optimal access of specialty care medicines to patients with significant medical needs, including key areas such as regulatory affairs, pharmacovigilance, medical affairs, pricing & reimbursement, quality and product distribution.

Immedica’s main owner is Impilo AB, a private Nordic investment company established in 2017, with more than SEK 3.6 billion in committed capital from leading Nordic and international investors.

For more information

Håkan Garpenstrand, Vice President, Head of Business Development, Immedica
hakan.garpenstrand@immedica.com

+46 708 80 29 32

Share on facebook
Share on twitter
Share on linkedin